CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Relamorelin 10 μgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018589 Gastroparesis NIH 0.45

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002578 Gastroparesis HPO 0.45

There is one clinical trial.

Clinical Trials

1 Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis

This open-label study is to assess the safety of continued treatment with Relamorelin for participants who previously completed the RLM-MD-03 or RLM-MD-04 study and to provide treatment for these participants until Relamorelin becomes commercially available or the Sponsor terminates development.

NCT03786380 Gastroparesis Drug: Relamorelin 10 μg
MeSH:Gastroparesis
HPO:Gastroparesis

Primary Outcomes

Measure: Proportion of adverse events in participants

Time: Through study completion: up to 5 years

Measure: Proportion of abnormal clinical laboratory values

Time: Baseline and every 3 months for up to 5 years

Measure: Proportion of abnormal vital signs

Time: Baseline and every 3 months for up to 5 years

Measure: Propotion of abnormal electrocardiograms

Time: Baseline and final visit: up to 5 years

Related HPO nodes (Using clinical trials)

HP:0002578: Gastroparesis
Genes 27
PINK1 TWNK POLG PARK7 TMEM70 TWNK LRRK2 POLG2 SNCA HTRA2 POLG POLG2 ATP7A PODXL POLG TYMP VPS13C POLG SLC25A4 SON TWNK SYNJ1 RRM2B UCHL1 PRKN DNAJC6 POLG
Protein Mutations 0
SNP 0